Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes

Erenumab is a monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) receptor suitable for episodic and chronic migraine prevention. Randomized clinical trials proved the superiority of erenumab to placebo in a strictly selected population, while real-world studies confirmed treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: De Matteis, Eleonora, Sacco, Simona, Ornello, Raffaele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994624/
https://www.ncbi.nlm.nih.gov/pubmed/35411146
http://dx.doi.org/10.2147/TCRM.S263825

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994624/
https://www.ncbi.nlm.nih.gov/pubmed/35411146
http://dx.doi.org/10.2147/TCRM.S263825

Ejemplares similares